Skip to main content
. Author manuscript; available in PMC: 2014 Mar 4.
Published in final edited form as: Sci Transl Med. 2013 May 29;5(187):187ra70. doi: 10.1126/scitranslmed.3005996

Fig. 5. HI activity of human sera after vaccination against pandemic 2009 H1N1.

Fig. 5

Pre- and post-vaccination sera samples obtained from 52 subjects enrolled in clinical trials to test the safety and immunogenicity of an inactivated 2009 H1N1 influenza vaccine, were tested for their HI activity against WT Neth/09 and the glycosylation mutant viruses. For each subject the difference in HI activity between post- and pre-vaccination (HI titer post-vaccination – HI titer pre-vaccination in number of wells) was determined to normalize for pre-existing HI activity. For each virus the distribution of increase in HI activity post vaccination is plotted. The median of the distribution is marked with a red line and statistically significant differences were determined with the Wilcoxon rank sum test.